1.Chaurasiya, S., Hew, P., Crosley, P., Sharon, D., Potts, K., Agopsowicz, K., Long, M., Shi, C. and Hitt, M.M., 2016. Breast cancer gene therapy using an adenovirus encoding human IL-2 under control of mammaglobin promoter/enhancer sequences. Cancer gene therapy.
2.Leisegang, M., Engels, B., Schreiber, K., Yew, P.Y., Kiyotani, K., Idel, C., Arina, A., Duraiswamy, J., Weichselbaum, R.R., Uckert, W. and Nakamura, Y., 2016. Eradication of large solid tumors by gene therapy with a T-cell receptor targeting a single cancer-specific point mutation. Clinical Cancer Research, 22(11), pp.2734-2743.
3.Ajith, T.A., 2015. Strategies used in the clinical trials of gene therapy for cancer. Journal of experimental therapeutics & oncology, 11(1).
4.Herman, J., 2016. Gene therapy and genome editing strategies for HIV resistance. Science Spotlight, 6(4).
5.Wagner, T.A., 2016. Combining cell and gene therapy in an effort to eradicate HIV. AIDS Patient Care and STDs, 30(12), pp.534-538.
6.DiGiusto, D.L., 2015. Stem cell gene therapy for HIV: strategies to inhibit viral entry and replication. Current HIV/AIDS Reports, 12(1), pp.79-87.
7.White, A.C. and Lowry, W.E., 2015. Refining the role for adult stem cells as cancer cells of origin. Trends in cell biology, 25(1), pp.11-20.
8.Hu, C., Niestroj, M., Yuan, D., Chang, S. and Chen, J., 2015. Treating cancer stem cells and cancer metastasis using glucose-coated gold nanoparticles. International journal of nanomedicine, 10, p.2065.
9.Takebe, N., Miele, L., Harris, P.J., Jeong, W., Bando, H., Kahn, M., Yang, S.X. and Ivy, S.P., 2015. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nature reviews Clinical oncology, 12(8), pp.445-464.
10.Obernier, K., Tong, C.K. and Alvarez-Buylla, A., 2015. Restricted nature of adult neural stem cells: re-evaluation of their potential for brain repair. Adult neurogenesis twenty years later: physiological function versus brain repair, p.21.
11.Huch, M., Gehart, H., van Boxtel, R., Hamer, K., Blokzijl, F., Verstegen, M.M., Ellis, E., van Wenum, M., Fuchs, S.A., de Ligt, J. and van de Wetering, M., 2015. Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell, 160(1), pp.299-312.
12.Bender, I.R., Lee, J.Y., Rudek, M.A., Dittmer, D.P., Ambinder, R.F. and Krown, S.E., 2016. Brief Report: A Phase 1b/Pharmacokinetic Trial of PTC299, a Novel PostTranscriptional VEGF Inhibitor, for AIDS-Related Kaposi's Sarcoma: AIDS Malignancy Consortium Trial 059. Journal of acquired immune deficiency syndromes (1999), 72(1), pp.52-57.
13.Kestier, H.W., Ringler, D.J., Mori, K., Panicali, D.L., Sehgal, P.K., Daniel, M.D. and Desrosiers, R.C., 1991. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell, 65(4), pp.651-662.
14.Li, N.C., Lee, A., Whitmer, R.A., Kivipelto, M., Lawler, E., Kazis, L.E. and Wolozin, B., 2010. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. Bmj, 340, p.b5465.
15.Vagnucci, A.H. and Li, W.W., 2003. Alzheimer's disease and angiogenesis. The Lancet, 361(9357), pp.605-608.
16.Rabey, J.M., Nissipeanu, P. and Korczyn, A.D., 1992. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. Journal of Neural Transmission-Parkinson's Disease and Dementia Section, 4(4), pp.277-282.
17.Zhang, H., Tong, R., Bai, L., Shi, J. and Ouyang, L., 2016. Emerging targets and new small molecule therapies in Parkinson’s disease treatment. Bioorganic & medicinal chemistry, 24(7), pp.1419-1430.
18.Poletti, V., Charrier, S., Martin, S., Gjata, B., Vignaud, A., Zhang, F., Buckland, K., Rothe, M., Schambach, A., Pai, S.Y. and Williams, D.A., 2016. Preclinical Development of Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1). Blood, 128(22), pp.4705-4705.
19.Chan, F., Humbert, O., Torgerson, T., Hubbard, N., O'Donnell, P., Humphrys, D.R., Adair, J.E., Felsburg, P., Trobridge, G.D., Scharenberg, A.M. and Rawlings, D.J., 2016. Rapid Expansion of Gene-Marked Lymphocytes in X-SCID Dogs after AMD3100+ G-CSF-Based Hematopoietic Stem/Progenitor Cell Mobilization and Intravenous Injection of a Common γ-Chain Expressing Foamy Viral Vector. Blood, 128(22), pp.1348-1348.
20.Acland, G.M., Aguirre, G.D., Ray, J., Zhang, Q., Aleman, T.S., Cideciyan, A.V., Pearce-Kelling, S.E., Anand, V., Zeng, Y., Maguire, A.M. and Jacobson, S.G., 2001. Gene therapy restores vision in a canine model of childhood blindness. Nature genetics, 28(1), pp.92-95.
21.Jacobson, S.G., Aleman, T.S., Cideciyan, A.V., Sumaroka, A., Schwartz, S.B., Windsor, E.A., Traboulsi, E.I., Heon, E., Pittler, S.J., Milam, A.H. and Maguire, A.M., 2005. Identifying photoreceptors in blind eyes caused by RPE65 mutations: prerequisite for human gene therapy success. Proceedings of the National Academy of Sciences, 102(17), pp.6177-6182.
22.Griesenbach, U. and Alton, E.W., 2013. Moving forward: cystic fibrosis gene therapy. Human molecular genetics, 22(R1), pp.R52-R58.
23.Paul-Smith, M.C., Bell, R.V., Alton, W.E., Alton, E.W. and Griesenbach, U., 2016. Gene therapy for cystic fibrosis: recent progress and current aims. Expert Opinion on Orphan Drugs, 4(6), pp.649-658.
24.Flotte, T.R. and Carter, B.J., 1995. Adeno-associated virus vectors for gene therapy. Gene therapy, 2(6), pp.357-362.
25.Kaplitt, M.G., Feigin, A., Tang, C., Fitzsimons, H.L., Mattis, P., Lawlor, P.A., Bland, R.J., Young, D., Strybing, K., Eidelberg, D. and During, M.J., 2007. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. The Lancet, 369(9579), pp.2097-2105.
26.Mingozzi, F. and High, K.A., 2013. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood, 122(1), pp.23-36.
27.Berry, G.E., 2016. Chemical modulation of AAV trafficking (Doctoral dissertation, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL).
28.Klatzmann, D., Valery, C.A., Bensimon, G., Marro, B., Boyer, O., Mokhtari, K., Diquet, B., Salzmann, J.L. and Philippon, J., 1998. A phase I/II study of herpes simplex virus type 1 thymidine kinase “suicide” gene therapy for recurrent glioblastoma. Human gene therapy, 9(17), pp.2595-2604.
29.Ginn, S.L., Alexander, I.E., Edelstein, M.L., Abedi, M.R. and Wixon, J., 2013. Gene therapy clinical trials worldwide to 2012–an update. The journal of gene medicine, 15(2), pp.65-77.
30.Craig, A.J. and Housley, G.D., 2016. Evaluation of Gene Therapy as an Intervention Strategy to Treat Brain Injury from Stroke. Frontiers in molecular neuroscience, 9.
31.Zaia, J.A., 2016. A New Agent in the Strategy to Cure AIDS. Molecular Therapy, 24(11), pp.1894-1896.
32.Luo, J., Luo, Y., Sun, J., Zhou, Y., Zhang, Y. and Yang, X., 2015. Adeno-associated virus-mediated cancer gene therapy: current status. Cancer letters, 356(2), pp.347-356.
33.Guidelines for maintaining cultured cells (no date) Available at: https://www.thermofisher.com/ie/en/home/references/gibco-cell-culture-basics/cell-culture-protocols/maintaining-cultured-cells.html (Accessed: 2 December 2016).
34.XRS 20 Bioreactor system (2016) Available at: https://www.pall.com/main/biopharmaceuticals/product.page?lid=hdf24174 (Accessed: 28 November 2016).
35.Zolotukhin, S., Byrne, B.J., Mason, E., Zolotukhin, I., Potter, M., Chesnut, K., Summerford, C., Samulski, R.J. and Muzyczka, N., 1999. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene therapy, 6(6), pp.973-985.
36.plc, H.D.G. (2016b) RAAV. Available at: https://www.horizondiscovery.com/gene-editing/raav (Accessed: 10 October 2016).
37.Jayapal, K.P., Wlaschin, K.F., Hu, W. and Yap, M.G., 2007. Recombinant protein therapeutics from CHO cells-20 years and counting. Chemical Engineering Progress, 103(10), p.40.
38.Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A. and Chapman, M.S., 2002. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proceedings of the National Academy of Sciences, 99(16), pp.10405-10410.
39.BioLabs, V. (2004) Vector Biolabs: FAQ for adeno-associated virus (AAV). Available at: http://vectorbiolabs.com/vbs/page.html?m=262&s=AAV%20FAQ (Accessed: 21 October 2016).
40.Privacy, S.-A.C. (2016) CHO platform - Chinese Hamster Ovary media and supplements. Available at: http://www.sigmaaldrich.com/life-science/cell-culture/serum-free-media/protein-expression-cho.html (Accessed: 5 November 2016).
41.Verma, I.M. and Somia, N., 1997. Gene therapy-promises, problems and prospects. Nature, 389(6648), pp.239-242.
42.Flotte, T.R. and Carter, B.J., 1995. Adeno-associated virus vectors for gene therapy. Gene therapy, 2(6), pp.357-362.
43.Hermonat, P.L., Quirk, J.G., Bishop, B.M. and Han, L., 1997. The packaging capacity of adeno‐associated virus (AAV) and the potential for wild‐type‐plus AAV gene therapy vectors. FEBS letters, 407(1), pp.78-84.
REFERENCES
OVERVIEW
We were asked by Bioplus Pharmaceutical to put to get a simple overview of our process for their operators, as many of them have not gained a third level education yet and do not understand some of the complex scientific terminology. Below is this simple overview.
We even now had a clearer picture of our project there was just some necessary steps to take to make our dream a reality. Our goal was to to produce therapeutic, genetically engineered viral vectors with the aim of replacing mutated, cancerous genes with those that are healthy and functional. However, we needed to agree on what virus we should to carry the corrected genes into the human body. We put a lot of time and effort into deciding this as there was a lot of different viruses used in gene therapy for cancer treatment. We found one paper that had a similar idea to our own and they used the Adeno-Associated Virus (AAV) as their vector, so we began to look deeper into AVV. We discovered that the virus causes a very mild immune response, lending further support to its apparent lack of pathogenicity. Just like when choosing the cell line we felt that safety was of highest important, when compared to the other three viruses that can been in the drawing below, AVV showed the least threat to initiate an immune response, so there so we’d decided to settle on the AAV.
The next meeting was a simple one, we now knew what are plan was. We could see it in our minds, so when we brought forth our findings from our research it was easy to identify the appropriate cell line. The mind map below clearly illustrates our three different approaches to choosing the appropriate cell line. As can be seen and stated in our last meeting we decided to choose our cell line based on the cost, the safety of the cell line and the replication speed of the cell line. In terms of cost and replication both bacteria and yeast were the ideal options, but for safety it was very obvious that mammalian cell were the appropriate choose. We decided that the safety of our product should be seen as more important than the cost and time consumption of the product. Using this bases and through much research reading scientific journeys we settled on Chinese Hamster Ovary cells.
When we met up again, we all brought with us our findings from the research we carried out. This was one of our longest meetings as we found it hard to decide on what topic to focus in on. Through much debate we decided to put our efforts in the Gene Therapy. We felt this technique was very interesting and had a great future in world of therapeutics and bioprocessing, as well through reading many research papers we found that we were not the first to think of this idea. We knew we could use this to our advantage though, we had information relating to our idea and could potentially use the ideas of others and manipulate them to suit our project. As can be seen from the mind map below there are many possible applications for gene therapy, during this meeting we researched some of these applications, we knew we only focus on one so we began to discuss what we felt was the most important. We decided that we should try and focus on the area of cancer, as cancer is one of the deadliest and well known diseases. Another thing to point out it, as cancer is such a big treat to the human race there was a lot of information on it. We were able to get a good understanding of the disease and use that information to come up with our own project. We knew what a bioprocess entailed so we had to try and integrate our idea into a possible bioprocess. The first area of importance was decided the type of cell line to use, this was vital step in our journey as choosing the wrong one could have serious implications down the line. Therefore we decided to focus just on three aspects in regards to the cell line. The cost, the safety and the replication of the cell line. We narrowed down the possible cell lines (Bacteria Insect Mammalian) and went away to do some research into them.
When we were tasked with this project we thought long and hard about all the different avenues with could go down. Bioprocessing has so many applications and it was impossible to explore all of them. So we decided to meet up at the very start and began brainstorming some ideas. As you can see above we came up with four possible areas to focus on. All were areas of interest to us and all were areas that focus on some of the major diseases in the world right now. We as a team decided to go away separately and research each topic, to gain an insight into each topic and also to see which way the future of bioprocessing is heading towards.
Below is our simple overview of our journey, it lays out our thought process during the course of our journey. We used the original drawings to show our exact thoughts. Throughout this journey our ours we learnt many things, and not just to do with our final product, but the many areas of bioprocessing. We hope you can enjoy our journey as much as we did and perhaps maybe you too have learnt something new.